Results 101 to 110 of about 779,609 (165)
Background: CT-P13 is the first biosimilar monoclonal antibody to infliximab (IFX); it has been approved for the same indications as its IFX counterpart in Hungary.
Nagy, Ferenc +4 more
core +2 more sources
Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies. [PDF]
Takeuchi T +8 more
europepmc +1 more source
Biosimilar CT-P13 in treating ulcerative colitis in the real world [PDF]
Davide G, Ribaldone, Marco, Astegiano
openaire +3 more sources
Background: CT-P13, the first biosimilar monoclonal antibody to infliximab (IFX), has previously been confirmed to be efficacious in inducing mucosal healing in ulcerative colitis (UC) patients.
Palatka Károly +25 more
core +1 more source
Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study. [PDF]
Smith PJ +19 more
europepmc +1 more source
Item does not contain fulltextBACKGROUND AND AIMS: The biosimilar of Remicade(R), CT-P13, recently entered the European market. Clinical data on switching from Remicade(R) to CT-P13 in inflammatory bowel disease [IBD] are scarce.
Hoentjen, F. +6 more
core +1 more source
Safety, efficacy, and drug survival of the infliximab biosimilar CT-P13 in post-marketing surveillance of Japanese patients with psoriasis. [PDF]
Morita A +5 more
europepmc +1 more source
CT-P13 biosimilar is non-inferior to infliximab [PDF]
openaire +2 more sources
Background: With the range of options available for the treatment of Crohn’s disease, therapy selection can be challenging in clinical practice. Comparative efficacy data are needed to clarify the relative position of the increasingly complex portfolio ...
Vassiliki Sinopoulou +7 more
doaj +1 more source
Background CT-P13 SC, a new subcutaneous (SC) formulation of biosimilar infliximab (IFX), was approved by the European Medicines Agency in 2020 for the treatment of radiographic axial spondyloarthritis (axSpA) in adult patients.
Xenofon Baraliakos +7 more
doaj +1 more source

